Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Revvity sells reagents and instruments for biological research and newborn screening.
The company renamed itself after selling its instruments business and concentrated on consumables: antibodies, assay kits, reagents. That is more profitable than instruments — consumables are bought continuously rather than once a decade, and a laboratory that has validated a method changes them reluctantly.
A separate line is newborn screening, mandated by law in many countries: the flow of samples does not depend on research budgets or the economic cycle. Risks: funding for science and biotech start-ups, demand in China and competition from larger suppliers of laboratory materials. The dividend is token.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Revvity, Inc. (RVTY) is a company in the Health care sector; its shares trade on NYSE.
The price of Revvity, Inc. (RVTY) on November 2, 2026 is 150.99 $, −3.83 % on the day. Over 52 weeks the stock traded between 81.22 $ and 166.25 $; the price now sits 82 % of the way up that range. Over the past year the price changed by +67.94 %. The P/E ratio is 73.47, which is above the sector median (24.61). Market capitalization is 17.45 billion $, rank 5 among 23 stocks of the same industry with a known capitalization.
Revvity, Inc. trades on NYSE under the ticker RVTY. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks RVTY has traded between 81.22 $ and 166.25 $. As of 2 November 2026 the price stood 86.43 % of the way from the 52-week low to the high.
Over one year RVTY shares rose 67.94 %; over six months they rose 72.80 %. Volatility over 90 days is 37.75 %. Dividends are not included: this is price change only, as of 2 November 2026.
RVTY trades at a price-to-earnings ratio of 73.5, above the sector median of 24.6. Price to sales is 6.0, above the sector median of 3.6. Price to book is 2.4, below the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Revvity, Inc. reported revenue of 2.9B $ and net income of 238M $ over the last four quarters. Net margin is 8.16 %. Revenue changed by +4.05 % year over year. Earnings per share are 2.08 $. Market capitalisation is 17.5B $.
RVTY has a return on equity of 3.29 %, above the sector median of −40.58 %. Return on assets is 1.97 %, above the sector median of −30.08 %. Operating margin is 12.32 %, above the sector median of −20.96 %.